ストックスクリーナーアプリを入手
2.43
4.72%
-0.11
アフターアワーズ：
2.45
0.02
+0.82%
前日終値:
$2.54
開ける：
$2.54
24時間の取引高:
375.41K
Relative Volume:
1.10
時価総額：
$308.17M
収益：
-
当期純損益:
$-57.09M
株価収益率:
-5.3797
EPS:
-0.4517
ネットキャッシュフロー:
$-51.43M
1週間 パフォーマンス:
+1.68%
1か月 パフォーマンス:
-7.63%
6か月 パフォーマンス:
+6.61%
1年 パフォーマンス:
+230.56%
1日の値動き範囲:
$2.405
$2.60
1週間の範囲:
$2.29
$2.60
52週間の値動き範囲:
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
名前
Nautilus Biotechnology Inc
セクター
電話
206-333-2001
住所
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.425 | 322.78M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | ダウングレード | Goldman | Neutral → Sell |
| 2024-06-27 | 開始されました | Guggenheim | Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2022-01-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 開始されました | Cowen | Outperform |
| 2021-08-04 | 開始されました | Goldman | Neutral |
| 2021-07-13 | 開始されました | Jefferies | Buy |
すべてを表示
Nautilus Biotechnology Inc (NAUT) 最新ニュース
Nautilus Biotechnology (NAUT) Holds Steady at $2.54 as Stock Consolidates Near Key LevelsLow Volatility Picks - Newser
NAUT Stock Price, Quote & Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Q1 2026 Earnings Surprise: EPS $-0.12, Up SignificantStock Analysis Community - Newser
Nautilus Biotechnology introduces Voyager Platform for precise tau proteoform analysis - Traders Union
NAUT Stock Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
TradingKey - TradingKey
Nautilus Biotechnology unveils Voyager Platform for quantifying 768 tau proteoforms at Tau Global 2026 - Traders Union
NAUT (Nautilus Biotechnology) quarterly results under review as market awaits full earnings disclosure and segment analysis.Social Buzz Stocks - Newser
Why Nautilus Biotechnology (NAUT) ability to execute stands out (Market Focus) 2026-05-06Trending Buy Opportunities - newser.com
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nautilus Biotechnology (NAUT) price target increased by 60.00% to 4.08 - MSN
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026 - MSN
What revision trend Nautilus Biotechnology (NAUT)? (Spikes) 2026-05-01Momentum Stock Picks - Newser
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Nautilus Biotechnology (NAUT) outlines 2026 shareholder votes on directors, pay and auditor - Stock Titan
Nautilus Biotechnology (NASDAQ: NAUT) details Q1 2026 loss and cash runway - Stock Titan
Nautilus Biotechnology Plans Voyager Platform Launch for Late 2026 - HarianBasis.co
Nautilus Biotechnology Q1 Earnings Call Highlights - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Nautilus Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast - Investing.com
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast By Investing.com - Investing.com Canada
Nautilus Biotechnology Q1 net loss narrows as expenses fall - TradingView
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Q1 2026: Nautilus Biotechnology (NASDAQ: NAUT) cuts costs and narrows loss - Stock Titan
Nautilus Biotechnology Appoints Amber Faust Vice Pres of Global Sales >NAUT - Moomoo
Sentinel Trust Co. LBA Purchases New Position in Nautilus Biotechnology, Inc. $NAUT - MarketBeat
Nautilus Biotechnology Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Nautilus Biotechnology launches recruitment drive for Iterative Mapping Early Access Program - Traders Union
Here is why Nautilus Biotechnology (NAUT) is one of the best life sciences penny stocks to buy - MSN
Nautilus Biotechnology CEO joins Biocom panel on AI impact in biotech sector - Traders Union
Nautilus Biotechnology (NAUT) Expected to Announce Earnings on Tuesday - MarketBeat
Nautilus Biotechnology (NAUT) Stock: Fair Value Assessment (Institutional Selling) 2026-04-20High Beta Stocks - vinhcong.tayninh.gov.vn
Nautilus Biotechnology details how artificial intelligence transforms proteomics insights - Traders Union
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy - Yahoo Finance
How does Nautilus Biotechnology Inc compare to its peersProduct Launch & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Published on: 2026-04-11 15:42:56 - baoquankhu1.vn
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026 - Investing News Network
NAUT PE Ratio & Valuation, Is NAUT Overvalued - Intellectia AI
NAUT Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-03-31 08:20:41 - baoquankhu1.vn
Nautilus Biotechnology Inc (NAUT) 財務データ
収益
当期純利益
現金流量
EPS
Nautilus Biotechnology Inc (NAUT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):